Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

Summary. Exacerbations of COPD are common and can be detrimental to both patient health and health care costs. Corticosteroids are recommended by consensus guidelines for patients during ...

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

COPD flare-ups to us are extremely serious because they are a marker that you are going to lose lung function. Thomas DeMarini, MD cont In other words, each exacerbation makes your lungs a little ...

Emphysema is a chronic lung condition that affects millions of people worldwide and can make everyday activities such as ...